In the 1770s Italian physician and physicist Luigi Galvani shocked the world with the discovery that a spark could cause a dead frog’s legs to twitch.

In 1802, German chemist Johann Wilhelm Ritter furthered Galvani’s research into electrophysiology. He observed how halting a strong current in muscle nerves could cause a muscle to contract.

Electricity as a medical therapy became a high-voltage field of interest. By the late 1800s, scientific literature described how electrical pulses could kill bacteria in river water or change the shape and color of red blood cells. Luminaries, such as Nikola Tesla, pioneered experiments and patented electrotherapeutic equipment.

Although electricity’s effect on the body had long been studied by the middle of the 20th century, many of the mechanisms were not yet known. In the 1950s, however, this began to change. For example, in 1951 Nobel Laureate in physiology or medicine Alan Lloyd Hodgkin theorized that the breakdown of a cell’s “skin” was at the root of many of electricity’s observed effects.

Hodgkin believed cellular membranes were electrically insulating layers, and that strong electricity caused pores to permanently open. Irreversibly opening pores made cells break apart and die. The phenomenon was dubbed electroporation, from the words “electric” and “pore.”

However, more experiments by other researchers eventually showed that irreversible electroporation wasn’t always the outcome of passing electricity through cells. Cellular pores are electrically charged gates. If pulses of electrical energy are sufficiently low and brief, existing gates open only temporarily. These cells don’t die, but this effect can still be useful. With electroporation, the ability of cellular membranes to keep a tight seal to the outside world can be manipulated for short periods of time.

As it turns out, the discovery of reversible electroporation revolutionized biotechnology research. Cracking open a cell’s pores allows researchers to get stuff into cells they weren’t able to before. By the 1980s, thanks to reversible electroporation, researchers were able to modify genes in everything from mouse cells to bacteria.

Today, electroporation equipment is a standard appliance in research labs. These devices, called electroporators, are used to create things like “knockout mice” — organisms with genes modified to study everything from cancer compounds to Alzheimer’s disease. Moreover, many of the new wonder drugs are biologics, which means they are produced by living organisms. Biologics often depend on the use of electroporation to create genetically modified cell lines to manufacture complex therapeutic proteins.

Up until recently electroporation has been limited to the lab. It is something used to introduce molecules that normally won’t be absorbed by cells while in culture. But that has changed…

Today this same technology is being applied for the treatment of cancer in living organisms — humans, to be exact…

You may already be familiar with some of this technology. I’ve been writing about it for some time.

Therapeutic engineered DNA molecules, known as plasmids, are an exciting, maturing platform for treating disease.

Plasmids are small rings of DNA that are used to turn cells into custom protein manufacturing plants. Once introduced into a cell, these genetic code constructs act like native DNA: they guide the production of proteins. This can include therapeutic proteins. The downside of DNA plasmids as agents to cure disease, however, is that they don’t migrate into a cell’s interior very well, if at all.

Electroporation solves the problem of DNA delivery. It has been used for this job in labs for decades. It can increase the ability of molecules like DNA to enter cells by 1,000 times or more.

Electroporation drug delivery can be used for far more than DNA vaccines. It can be used to deliver DNA designed for other purposes, as well as for improving the uptake of therapeutic molecules that are already on the market…

One use of gene therapies involves injecting directly into tumors.

This focuses on writing the code for these naturally occurring anti-cancer agents in its DNA plasmids, and then introduces them into tumor cells via electroporation.

Normally, the immune system works to seek and destroy cells that develop mutations. Sometimes, however, mutated cells develop the ability to defend themselves by hiding from the immune system. Alerting the immune system with these signaling proteins allows the immune system to recognize cancer cells and triggers a cascade reaction to destroy them.

Early investors in the technology will be on track to reap rich rewards from breakthrough electroporation platforms… it addresses a huge market.

Yours for transformational profits,

Patrick Cox
for The Penny Sleuth

An Electrifying Biotechnology – A Shot at Shocking Profits was originally featured in the Penny Sleuth.

In the process, they have done very well.

This sort of investing is not “trading” in the sense that the word is used to describe efforts to beat the market. Traders normally try to anticipate trends and act before the market moves. Trading the channel is the opposite strategy. Those who utilize this technique buy a stock that they would like to own more of after an event pushes a stock down. Channel traders buy for the long run, but often take profits when the stock goes back up.

For that reason, I’ve been talking to some of the other analysts at Agora to devise a strategy to help investors recognize channel trading opportunities. This will probably take the form of a ranking of companies in my portfolio based on my degree of certainty and/or urgency.

Here’s a great example…

I’ve written often about BioTime because of a string of important developments. These developments include the addition of Dr. Andrew von Eschenbach, ex-FDA head and noted cancer fighter, to the BioTime team. His confidence in BioTime’s recently announced pan-cancer diagnostic technology, a simple blood test that could easily replace dozens of separate and expensive tests, has to be seen as an important event.

Similarly, the announcement that BioTime, in conjunction with the Wistar Institute, has cracked the DNA reprogramming code, via the SP100 gene, is huge news. Not only will this discovery give BioTime the ability to safely reprogram cells for use in regenerative medicine, I believe most other stem cell companies will eventually have to pay BioTime for the right to use the technology.

There are other developments in the BioTime stable of subsidiaries as well. Today, however, my interest has been peaked by a blatant short attack on BioTime…

So-called analysts are doing everything they can to paint the company as a hollow shell. While such unscrupulous tactics make life uncomfortable for the executives of the companies under assault, they do provide opportunities for investors to increase holdings.

BioTime is the only stem cell company with a Big Pharma deal, the Teva/Cell Cure Neurosciences collaboration for macular degeneration in Israel. BioTime subsidiaries are also established in Singapore, Shanghai and Hong Kong. Because endothelial precursor therapy would involve a simple transfusion after the cells are prepared, it is a perfect candidate for health tourism.

This is why I believe that BioTime, at current low prices, is a perfect channel trading opportunity.

Yours for transformational profits,

Patrick Cox
for The Penny Sleuth

Finding Your Best Opportunities Right Now was originally featured in the Penny Sleuth.

This current work seems to have come up with a treatment that makes patients lose weight. How does it work?

It goes right after fat cells themselves…

The super-simple way to explain it is that this treatment cuts off the blood cells that supply fat cells. If you cut off the blood cells, fat can’t get into the fat cells, and the fat cells empty out… and die.

First, doctors tested this breakthrough on mice. It worked. Mice were fed a high fat diet for a period of time, then given doses of this treatment. The results were dramatic. If this testing translates to humans, it could become the biggest public health story in decades…

Then, rhesus monkeys — which share 93% of our genetic code — received the same treatment.

The breakthrough worked on the monkeys, too. In 30 days, these monkeys had achieved a new, healthy “set point”. I’m talking about overweight and obese subjects losing 10 — 15% of total body mass…in a month. Imagine the implications of this news…

Your “set point” is like a scale in perfect balance. It’s when your body chemistry is perfectly aligned and you’re as healthy as you can be.

A healthy set point for most obese people, in 30 days or less. That’s a true weight loss and heart health revolution.

Weight loss and heart health combine for hundreds of billions of dollars in spending every year. Over just a few years, we’re talking trillions.

And remember, this need grows by 10,000 people every single day…or 300,000 per month. That’s 3.6 million new folks every year — 45% of whom, or 1,620,000, are overweight.

So it’s not an overstatement to say a weight loss solution that actually worked, not only would it obliterate hundreds of billions in healthcare spending…

It would also rocket, maybe even overnight, to the top of the $65 billion weight loss industry in America today.

As of 2012, there is only one FDA approved weight loss drug in America. It’s called Xenical. Roche distributes it in most countries. In the U.S. and the U.K., GlaxoSmithKline sells it over the counter as Alli.

Basically, Alli stops your body from being able to absorb fat. Fat, unabsorbed, passes through your system and you void it. Or you could just not eat fat, and you wouldn’t need Alli.

My point is, there’s ONE approved weight loss treatment in America today. And frankly, it isn’t that great.

That’s why this research is so important. When the medical community begins to take notice, this new, effective weight loss alternative has the promise to take over the entire industry.

Yours for transformational profits,

Patrick Cox
for The Penny Sleuth

Groundbreaking Weight Loss Research Shows Extraordinary Results was originally featured in the Penny Sleuth.

Today, the disease is found throughout the world because of migrations from these regions.

Ordinarily, red blood cells have a doughnut-like shape. Individuals with the sickle cell trait, however, also have red blood cells that assume a crescent shape. This sickle cell’s shape confers resistance to the malaria parasite, plasmodium falciparum, which infects red blood cells.

Although the genetic mutation that causes sickle-shaped red blood cells helps people survive in regions plagued by malaria-carrying mosquitoes, it comes at a high price…

In individuals that carry two copies of the gene, for example, anemia is common, since the mutation reduces the ability of red blood cells to transport oxygen from the lungs to other parts of the body. This condition is called sickle cell disease (SCD).

However, on a purely physical level, sickle-shaped red blood cells can cause other problems as well. Since they aren’t as round as normal red blood cells, they don’t flow as well through the 60,000 miles of small, serpentine blood vessels that carry life-sustaining oxygen and nutrients to the body.

Normally, the percentage of sickle-shaped cells is low enough that this isn’t a big problem.

When the percentage of affected red blood cells in the body is high enough, however, a vaso-occlusive crisis can occur. When there are too many sickle-shaped red blood cells in the body, they clog in narrow capillaries like logs in a river bend. This occlusion in the blood vessels restricts blood supply to tissues, and can lead to pain and the death of cells in the affected areas.

The early symptoms are an imminent, looming pain in the body, much like the early stages of a flu infection. The pain eventually builds, and patients commonly describe it as being repeatedly hit with a baseball bat in the same place.

Female sufferers describe the pain as worse than childbirth.

In the United States alone, some 90,000 people are affected by SCD. It is most commonly found in people of African or Hispanic ancestry. In the U.S., 150,000 hospitalizations and E.R. visits are attributed to an SCD-caused crisis each year.

Patients suffering a crisis are administered intravenous narcotics and kept hydrated. They are monitored until the condition clears and then they are sent home. Typical hospital stays range from four–six days, but they can last up to two weeks. Other than waiting for the clogged blood cells to break down while administering analgesics to deal with the extreme pain, there are no good options to deal with the effects of an acute SCD condition. Extreme cases can cause death.

Even if it doesn’t kill immediately, SCD-caused crisis eventually shortens the life span of otherwise healthy people. Frequent clogging of blood flow can lead to early organ failure and death. A 1994 study, for example, showed the median age of death for SCD sufferers in the U.S. at 42 years for males, and 48 for females.

However, what if there were a way to help blood flow better in patients experiencing this condition? Not only could the duration of a crisis be reduced, but the amount of damage that one could cause would be reduced as well.

Yours for transformational profits,

Patrick Cox
for The Penny Sleuth

Solving the Sickle Cell Crisis was originally featured in the Penny Sleuth.

In my opinion,there is no company that has a bigger platform and a more undervalued stock…

The platform is nonembryonic human parthenogenetic (often shortened to “parthenogenic”) stem cells (hpSCs). The company in question developed a way to make pluripotent stem cells using unused oocytes (immature unfertilized ova or eggs) gathered in the process of in vitro fertilization.

As a result, it owns the intellectual property on these remarkable cells.

There a number of advantages inherent in these hpSCs. One is that those who are opposed to the use of embryonic cells in therapies need not worry.

Cells made from these lines could be manufactured and kept ready for use at any time. Once you have determined your cell type, like your blood types, you could buy specific stem cells “off the shelf” for whatever purpose you have. And, in most cases, the differentiated hpSCs could be used with little or no immune suppression.

Some people believe that the actual number of hpSC lines needed to treat 85% of all humans is as few as ten. The company is in the process right now of finding the right oocyte donors and creating those hpSC lines.

Currently, the company is moving ahead in four principal areas: retinal, corneal, liver and neural cells. The eye tissues will, I suspect, come to market first. There are tens of millions of people in Asia whose sight could be restored if they had access to transplant eye tissues. Because the infrastructure for organ donations does not exist, however, Asian scientists are enormously excited about bringing hpSC retinal and corneal tissues to their populations.

While growing parthenogenic corneal stem cells for research purposes, beautiful sphere or orbs of human eye tissue formed spontaneously, pointing to the power of these stem cells.

Though no one had set out to produce artificial eyes for the purpose of product testing, it was an obvious possibility. Draize testing is a method for testing chemicals used in all kinds of products, from cosmetics and cleaning supplies to drugs and perfumes, for human safety. The actual procedure involves applying the chemicals to living animals’ eyes. Then, the eyes are often removed for testing.

Tests performed indicate that the hpSCs perform as well as, if not better than, animal eyes as a predictor for toxicity. This isn’t surprising, as the orbs are living human cells.

Needless to say, this is an important milestone, as Draize testing is currently a multibillion-dollar industry and everyone would like to see the procedure minimized. If animal lovers realize that there is now an alternative, I think the pressure to buy corneal orbs will be significant…

Yours for transformational profits,

Patrick Cox
for The Penny Sleuth

Tap Into The $64 Billion Stem Cell Market was originally featured in the Penny Sleuth.

I’m still astounded by one announcement made recently…

Scientists have identified the gene that locks down inactive DNA — SP100.

Let me explain.

The SP100 gene expresses an RNA protein that keep portions of the genome that shouldn’t be activated locked down. This is critical because every cell in your body contains the entire vast genome, containing all of the information necessary to become all of our many thousands of cell types.

Also contained in every cell’s DNA is the instruction code that controls the incredible complexity of the way that each of these thousands of cell types interacts with every other cell in the body.

It’s really quite stunning when you think about it.

Obviously, any individual cell contains genes that are not active. Some of them are genes that are not active in that particular cell type. Others that are protected from activation or transcription are the genes that determine what a cell’s identity is.

You would not, for example, want toenail cell genes activated in heart valves or bone genes activated in your eyes.

But, it is possible for any cell to become any other cell type — if you know the genetic code and the right gene switches…

Because genes can be accidentally activated by various factors, including natural cosmic rays, cells keep much of the genome in a protected, secure state, except when the cell is first developing or when it is replicating. The genes in the protected or silenced state are part of the heterochromatin, in which the DNA is tightly folded.

The gene that keeps the heterochromatin folded and protected from transcription — under most circumstances — is the SP100 gene. Now that this is known, it is possible to block the SP100 gene’s activity in a number of ways, such as short interfering RNA.

When SP100 gene activity is blocked, the genes that are protected inside the heterochromatin are available for reprogramming. In terms of regenerative medicine, the most-important reprogramming is the conversion of a cell to induced pluripotent stem (iPS) cell status. These rejuvenated, immortalized cells have the same potential to become other cells as embryonic cells.

This discovery will accelerate regenerative medicine and enable untold numbers of therapies.

When different cell types can be made easily, everything from heart disease to lactose intolerance and diabetes will be curable. It should and probably will result in a Nobel Prize when its importance becomes evident.

One study in which muscle progenitor stem cells were given to prematurely aged mice, resulting in amazing rejuvenation, even though the cells didn’t actually become part of the host animals. Stem cells are producers of remarkable growth hormones and other substances that hold remarkable regenerative powers. I like this particular article because one scientist mentions that the transformation in the mice was so amazing that he thought that the old mice had been switched with young ones.

The point, though, is that the SP100 gene discovery is going to help make this sort of therapy possible for humans. It will enable rapid, reliable conversion of your cells to iPS, and then immune-matched therapeutic cells.

I guarantee that I’ll have much more on this for you in the near future. This is one of the biggest victories in the battle against disease and aging in my lifetime.

This is a great time to be alive and investing.

Yours for transformational profits,

Patrick Cox
for The Penny Sleuth

A Nobel-Worthy Stem Cell Discovery was originally featured in the Penny Sleuth.

Briefly, galectins-3s are proteins that have the ability to recognize and attach themselves to specific sugar molecules. This sugar-binding characteristic is typical of all lectins and is essential to our bodies’ functioning, but galectin-3s, for some reason, are also involved in all manner of disorders. Galectin-3s are integrally involved in strokes, heart disease, cancers, inflammation and fibrosis in its many health-destroying forms.

One of the bad things that galectin-3s does is attach to T-cells. T-cells are the white blood cells or lymphocytes that fight disease and communicate information about threats to the immune system.

The “T” in T-cells, by the way, stands for thymus. That’s because T-cells are born in your bone marrow but then migrate to the heart-shaped thymus, located behind the sternum in the center of your chest. There, they mature and are programmed for specific purposes.

This programming is based in part on information about any disease in your body that is contained in the thymus. That information is relayed to the thymus by other T-cells that circulate through your body. This complex information transfer process is not static. It evolves as the body tests different approaches to fighting threats.

In theory, this thymus-regulated immune process should be able to deal easily with cancers. Unfortunately, cancers can escape routine detection and destruction by T-cells by making a deadly fog or shield of galectin-3s. They attach to the T-cells that approach the cancer, triggering cell suicide in the cancer-fighting lymphocytes. As a result, the T-cells are prevented from doing battle with the cancer cells and cannot report back to the thymus. The cancer, in turn, evolves like a malignant intelligence — hidden behind the galectin-3 death fog.

The Ludwig Institute, the world’s largest and one of the most respected cancer research organizations, tested one of these carbohydrate drugs in cultures of cancer cells mixed with T-cells. As expected, the cancer cells quickly shut down the T-cells with galectin-3s. Into this mix of doomed T-cells and cancer cells, the galectin-3 blocking drug was added. Immediately, the T-cells were rejuvenated and began killing cancers.

Cancer vaccine therapies are one of the hottest areas of biotech research today. At least a hundred organizations, I hear, are currently looking for vaccination therapies that train T-cells to more effectively fight cancers. This is only logical, since prior anti-cancer therapies have been, by definition, toxic. Both chemotherapy and radiation therapy harm the patient. The trick is to harm the cancer more, but it is not an optimal solution. Prior to new approaches to cancer, the best possible scenario was to reduce side effects and damage. In fact, the drug in question drug does that, but the industry is far more interested in nontoxic approaches to fighting cancer.

Ludwig, for example, is investing in clinical trials because they believe, as I do, that the immune system, and therefore vaccines, will work far better when T-cells are protected from galectin-3s. If it works with Ludwig’s particular vaccine, however, it will work with any cancer vaccine. This opens up a vast market.

The important thing to keep in mind regarding this trial is that the galectin-3 blocker would improve the vaccine result even if it didn’t actually interact with the immune process to increase the vaccine’s efficacy. Through the course of my research, I’ve learned that cell culture tests showed that this drug resurrected T-cells so that they killed cancers.

This means that the drug on its own could be a very potent cancer killer. I predict that it will be, in fact. Given periodically, I believe it will work prophylactically to prevent cancers.

Yours for transformational profits,

Patrick Cox
for The Penny Sleuth

Outwitting Cancer’s “Deadly Fog” was originally featured in the Penny Sleuth.

We tend not to think about it, but the single-cell microorganisms categorized as bacteria are the dominant life form on Earth. In some mathematical sense, this is their planet and we just use it.

Their total biomass, after all, is greater than that of all living plants and animals combined. Bacteria inhabit the planet from the highest peaks to the deepest depths of the ocean. There are typically 40 million bacteria in one gram of soil and a million in a milliliter of fresh water. In our bodies, bacteria outnumber human cells 10 to one.

Besides making extremely useful things possible, including Rioja wines, single-malt scotches and the Earth’s biosphere, bacteria can also cause serious problems. Bacterial infection, in fact, may be the single largest killer in America today.

However, we don’t hear about a bacterial plague for several reasons…

One is that some pre-existing conditions, such as diabetes or a virus-borne disease, often create the conditions that lead to an opportunistic bacterial infection. So statisticians tend to categorize deaths according to the condition that led to the lethal infection that actually killed the patient.

Also, I suspect that the medical profession doesn’t like to talk about the danger of infections that are often acquired in hospitals, though I may be too cynical.

Regardless, some estimates are that bacteria cause, in the U.S. alone, over 14 million skin and soft tissue infections, and 7 million methicillin-resistant Staphylococcus aureus (MRSA) cases, annually. Of those infections, 70% are resistant to at least one antibiotic.

Moreover, resistance is growing due to natural evolutionary mechanisms as well as the misuse and overprescription of antibiotics.

Just a few weeks ago, the world medical community suffered a serious scare when an Indian clinic announced it had a dozen patients with highly contagious tuberculosis resistant to all known antibiotics. A totally untreatable TB could, in fact, easily kill hundreds of millions and send Western economies into a long depression.

Fortunately, the announcement was false. A therapy was found and the epidemic prevented.

Still, the trend lines are clear, and public perception of this threat is growing.

There are companies, however, that continue to make serious progress in the goal of creating new and effective antibiotics that bacteria could not adapt to.

With a $10 billion market that is rapidly growing, the potential rewards are stratospheric. Investors would be wise to pay attention to companies working to create new effective antibiotics…

As concern over the fading effectiveness of antibiotics grows, investor attention will turn to the few companies working on solutions. Now is the time to act… before everyone else does.

Yours for transformational profits,

Patrick Cox
for The Penny Sleuth

Why You Can’t Ignore the Growing Antibiotic Market was originally featured in the Penny Sleuth.

It is, I think, the hallmark of our era.

Things we thought were impossible are coming to pass on a regular basis. To prosper, we’ll all have to re-examine practically everything we thought we could take for granted…

I realize that the economic situation created by our feckless ruling class tends to cast a cold pallor on the world. It is depressing, I admit, but it will pass. The real story going on behind the scenes is an unbelievable number of technological breakthroughs.

These are not hypothetical breakthroughs. They have already occurred, but are not yet fully deployed.

They will, in turn, drive astonishing progress and growth, as well as enormous wealth for those with the vision to help it along through investments…

Last week, I told you about the release of the first published data about the effects of a nutraceutical from one tiny company. The clinical study revealed that low doses of this substance reduced C-reactive proteins (CRP) in obese smokers by a third. Also, we know from animal and cell studies that higher doses reduce inflammation significantly further.

This is, frankly, remarkable.

This naturally occurring alkaloid from the solanaceous plant family is more effective than the statins for lowering CRPs, while lacking their sometimes dangerous side effects. We know from cell and animal studies that other markers of inflammation, including interleukin-1 and -6 as well as tumor necrosis factor, are also reduced in a dose-dependent fashion.

This tells me that this substance is not simply taking out the markers, but is actually preventing their creation by directly addressing autoimmune inflammation.

This ability to prevent the misfiring of the immune system’s activator gene, NF-kappaB, means that many of the diseases caused by autoimmune inflammation will be significantly delayed if not actually prevented. This translates into much-longer healthy life spans…

For me, personally, this substance has nearly eliminated a number of age-related inflammatory disorders that afflicted me only a year ago. Cervical arthritis, BPH and even gingivitis continue to improve. The most-amusing change, however, has been the reversal of hair loss, which is being reported by many users. Though hair is not — in and of itself — important, it is meaningful as an indicator of efficacy.

The Tipping Point Approaches…

Several people have asked me recently why the company’s stock does not yet reflect the reality of its technologies. I sort of take for granted that people understand these things, but apparently, I should not.

Right now, the vast majority of investors simply aren’t equipped to understand the science behind this breakthrough nutraceutical. Most investors get their information from bulletin boards and financial websites often filled with contradictory and fallacious claims.

We know that more news will come forth from a massive study. It is double-blinded data, and I am convinced that it will also validate this substance’s efficacy.

Yours for transformational profits,

Patrick Cox
for The Penny Sleuth

A World-Changing Technology was originally featured in the Penny Sleuth.

In scientific circles, this type of anecdotal evidence, no matter how persuasive, cannot be relied on or cited. Those are the rules, even if they’re regularly broken.

Economists and analysts, however, have different rules. We make predictions that scientists cannot make, at least publicly…

I predicted that further research would prove that this substance citrate is one of the most important breakthroughs in modern medicine. This is because I am convinced of its ability to halt or ameliorate the underlying mechanisms of autoimmune disorders, in part at least from personal experience.

Therefore, I am enormously gratified to see the first clinical data validate my assumptions and predictions. We don’t yet have multiple double-blind studies, but first published results are, in a word, stunning.

Data was just released regarding this substance’s impact on hs-CRP (high-sensitivity C-reactive proteins).

CRP levels, as you know, are strong indicators of various medical conditions as well as general health. High CRP levels are associated with increased risk of diseases ranging from heart disease to cancers.

The bottom line is that low doses of this substance dropped highly sensitive C-reactive protein levels by about a third in test group of mostly obese smokers. Because reductions in CRP levels have the most impact on health when they are high, these reductions are extremely meaningful.

Though it is not blinded data, it is still extremely meaningful. We already knew, from animal and cell studies, that this substance outperformed other anti-inflammatories ranging from Lipitor, aspirin and ibuprofen to Celebrex.

Until now there had been no clinical evidence that this substance works as well in human studies as it does in cell and animal studies. This is, therefore, an important point in the history of this technology…

Remember, numerous studies link statin use to reduced risk of heart and other diseases. Others believe that inflammation is the driver behind most cancers.

When all is said and done, I believe the impact of widespread use of this substance will have a profound impact on our demography as well as investors’ bank accounts…

Yours for transformational profits,

Patrick Cox
for The Penny Sleuth

One of the Most Important Breakthroughs in Modern Medicine was originally featured in the Penny Sleuth.